- 专利标题： 3-ARYL- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONEDEACETYLASE 6 (HDAC6) INHIBITORS
-
申请号： US16309390申请日： 2017-06-19
-
公开(公告)号： US20190185462A1公开(公告)日： 2019-06-20
- 发明人: Abbas Walji , Richard Berger , Craig A. Stump , Kelly Ann S. Schlegel , James J. Mulhearn , Thomas J. Greshock , Deping Wang , Mark E. Fraley , Kristen G. Jones
- 申请人： Merck Sharp & Dohme Corp.
- 申请人地址： US NJ Rahway
- 专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人地址： US NJ Rahway
- 国际申请： PCT/US17/38067 WO 20170619
- 主分类号： C07D413/10
- IPC分类号： C07D413/10 ; C07D413/14 ; C07D413/04 ; C07D413/12 ; C07D417/12 ; C07D417/14 ; C07D471/04 ; C07D487/04 ; C07D491/048 ; C07D491/052 ; C07D498/04 ; C07D513/04 ; C07D271/06 ; C07D471/14 ; A61P25/28 ; A61P25/18 ; A61P29/00 ; A61P11/06 ; A61P3/10 ; A61P35/00 ; A61P37/02
摘要：
The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.
公开/授权文献
信息查询
